Immune System News and Research

RSS

CryoLife's SynerGraft technology effective in removing donor cells and cellular remnants from the tissue

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced the first three implantations of the CryoPatch((R)) SG pulmonary human cardiac patch since FDA clearance.

19 Aug 2009

ACE inhibitors and AT1R blockers suppress inflammation in mice

Conventional blood pressure medication can treat inflammation in an animal model mimicking multiple sclerosis (MS). This discovery was made by Dr. Michael Platten, head consultant at the department of Neurooncology at Heidelberg University Hospital and head of the Helmholtz Experimental Neuroimmunology Junior Research Group on at the German Cancer Research Center and his team in cooperation with scientists from Stanford University in California.

19 Aug 2009

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting on September 2, 2009.

18 Aug 2009

FDA approves Extavia for multiple sclerosis

The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

17 Aug 2009

Mother's immune system may block fetal treatments for blood diseases

Pediatric researchers have resolved an apparent contradiction in the field of prenatal cell transplantation - a medical approach that holds future promise in correcting sickle cell disease and other serious congenital blood disorders. In a new study in animals, the researchers showed that the mother's immune response interferes with the offspring's earlier ability to tolerate transplanted donor cells.

17 Aug 2009

New biomarker predicts response to hepatitis C treatment

Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference. Duke University Medical Center scientists says the biomarker not only predicts who is most likely to respond to treatment and who isn't, but also may explain why there are such different rates of response among racial and ethnic groups, a phenomenon that has puzzled physicians for years.

16 Aug 2009

New strategy for inhibiting virus replication

Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.

16 Aug 2009

New microneedle-based injection device from Nanopass

Following the World Health Organization (WHO) declaration of a swine flu pandemic, NanoPass Technologies Ltd. (NanoPass) announced today that it has successfully developed a microneedle-based injection device that could dramatically enhance both the effectiveness and supply of pandemic flu vaccines.

14 Aug 2009

New immune therapy for kidney cancer tested

Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial to evaluate whether the standard treatment for a common form of kidney cancer works better by itself or when combined with a certain type of blood cell that comes from a patient’s relative. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

14 Aug 2009

Herbal supplements aren't always safe!

Natural doesn’t always mean safe when it comes to herbal supplements, according to the August issue of Mayo Clinic Health Letter.

13 Aug 2009

When cell death goes wrong - scientists gain new insights

Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells are prompted to die. The work may help scientists to eventually develop new treatments for the many common diseases and conditions which occur when cell death goes wrong.

13 Aug 2009

Opinion: U.S. global health strategy; fighting drought

As the U.S. "works on a comprehensive global health strategy," we need to "expand our thinking to encompass holistic solutions that go into improving the health of the world’s poor," Bill Frist, former U.S. Senate Majority leader and current member of the Millennium Challenge Corporation's (MCC) Board of Directors, writes in a Boston Globe opinion piece.

13 Aug 2009

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

The first batch of NY-ESO-1 recombinant protein produced in a facility supported entirely by non-profit entities has successfully cleared regulatory review and has entered clinical testing. The clinical trials are part of the Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd. (LICR).

13 Aug 2009

Medical imaging: The good, the bad and the ugly

In the political minefield of healthcare reform, medical imaging has emerged as a microcosm of this contentious debate. Congress has been charged with a high stakes, high wire balancing act: to create a bill preserving quality and access while trimming unethical and unnecessary spending. Medical imaging represents such a challenge, with its undeniable benefits tainted by inappropriate use.

13 Aug 2009

Antigenics’ Oncophage cancer vaccine trial starts enrolling patients

Antigenics Inc. (NASDAQ:AGEN) today announced that the Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a Phase 2 clinical trial of Oncophage (vitespen) in combination with the standard of care - radiation therapy plus Temodar (temozolomide) - for newly diagnosed glioma patients.

13 Aug 2009

Dynavax announces European development strategy for investigational adult hepatitis B vaccine in Europe

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that it has met with the European Medicines Evaluation Agency (EMEA) to discuss its plans for continued clinical development of HEPLISAVTM Phase 3 investigational adult hepatitis B vaccine in Europe.

12 Aug 2009

Cryolife receives 510(k) clearance from FDA for CryoPatch SG pulmonary human cardiac patch

CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CryoPatch((R)) SG pulmonary human cardiac patch.

12 Aug 2009

Cannabis Science reports on future plans for cannabis drug trials

Cannabis Science, Inc. (OTCBB: CBIS) has announced that it has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials.

12 Aug 2009

Research on blood transfusions points to a potential risk of transfusing donated platelets

Doctors have noticed a pattern in performing bone marrow transplants as a cure for diseases involving bone marrow failure: more transfusions before a bone marrow transplant correlates with a higher likelihood of rejection, says James Zimring, MD, PhD, assistant professor of pathology and laboratory medicine at Emory University School of Medicine.

12 Aug 2009

Pennsylvania's first case of West Nile in 2009 confirmed

State Health Secretary Everette James today reported this year's first confirmed human case of West Nile virus in Pennsylvania. The individual is a 21-year-old woman from Luzerne County.

12 Aug 2009